Research Topics
| Norman M KnetemanSummaryAffiliation: University of Alberta Country: Canada Publications
| Collaborators
|
Detail Information
Publications
Impact of calcineurin inhibitors with or without interferon on hepatitis C virus titers in a chimeric mouse model of hepatitis C virus infectionNorman M Kneteman
Division of Transplantation, Department of Surgery, University of Alberta, 8440 112 Street NW, Edmonton, AB, Canada
Liver Transpl 18:38-44. 2012..7%) achieved a 1-log decline in the HCV titer (P = 1). Using this animal model, we could find no evidence supporting the routine use of CSA after LT in HCV-infected patients...- HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virusNorman M Kneteman
KMT Hepatech, Inc, Edmonton, Alberta, Canada
Hepatology 49:745-52. 2009..These outcomes demonstrate the utility of the range of in vitro and in vivo models now available for anti-HCV drug development and support the potential utility of polymerase inhibitors in future combination therapies for HCV treatment... 
De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effectsChristian Toso
Department of Surgery, Section of Hepatobiliary, Pancreatic and Transplant Surgery, University of Alberta, Edmonton, Canada
Transplantation 83:1162-8. 2007..We report long-term outcomes and side effects after transplantation for hepatocellular carcinoma (HCC) using de novo, sirolimus-based immunosuppression (IS)...- Long-term graft function after allogeneic islet transplantationJonathan R T Lakey
Clinical Islet Transplant Program, University of Alberta and Capital Health Authority, Edmonton, Alberta, Canada
Cell Transplant 16:441-6. 2007..In contrast, sustained insulin secretion with nearly normal HbA1c at 13 years follow-up was observed in another patient, providing hope for improving long-term graft outcomes for islet transplant recipient... - Factors affecting hepatocyte isolation, engraftment, and replication in an in vivo modelToshiyasu Kawahara
Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
Liver Transpl 16:974-82. 2010.... - The portal immunosuppressive storm: relevance to islet transplantation?A M James Shapiro
Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
Ther Drug Monit 27:35-7. 2005..This "portal storm" of immunosuppression may be relevant to intrahepatic islet transplantation... - Sirolimus-induced ulceration of the small bowel in islet transplant recipients: report of two casesMichele Molinari
Department of Surgery, Clinical Islet Transplant Program, University of Alberta, Edmonton, Alberta, Canada
Am J Transplant 5:2799-804. 2005..Our experience highlights an uncommon but potentially serious adverse effect of high-dose SRL in islet recipients... - Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinomaChristian Toso
Section of Hepatobiliary, Pancreatic, and Transplant Surgery, University of Alberta, Edmonton, Canada
Liver Transpl 14:1107-15. 2008.... - ABO-incompatible liver transplantation for critically ill adult patientsChristian Toso
Department of Surgery, Section of Hepatobiliary, Pancreatic and Transplant Surgery, University of Alberta, Edmonton, Canada
Transpl Int 20:675-81. 2007..Our results suggest that ABO-incompatible transplants should be viewed as an important therapeutic option in adult patients with acute liver failure awaiting an emergency procedure... 
The impact of sirolimus on hepatitis C recurrence after liver transplantationSonal Asthana
Department of Surgery, University of Alberta, Edmonton, Alberta
Can J Gastroenterol 25:28-34. 2011..While some immunosuppression strategies may accelerate hepatitis C virus (HCV) recurrence after liver transplantation (LT), the impact of sirolimus (SRL) is not known...- The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinomaShaheed Merani
Department of Surgery, University of Alberta, Edmonton, Canada
J Hepatol 55:814-9. 2011..Liver transplantation is a recognized treatment for selected patients with hepatocellular carcinoma (HCC), but transplant criteria still need to be refined, especially in the case of more advanced or downstaged tumors... - Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinomaChristian Toso
Section of Hepatobiliary, Pancreatic and Transplant Surgery, University of Alberta, Edmonton, Canada
Hepatology 51:1237-43. 2010..Conclusion: According to these data, sirolimus-based immunosuppression has unique posttransplant effects on HCC patients that lead to improved survival... - Critical role of natural killer cells in the rejection of human hepatocytes after xenotransplantation into immunodeficient miceToshiyasu Kawahara
Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
Transpl Int 23:934-43. 2010..These results support a critical role for mouse NK cells in the rejection of human hepatocytes xenotransplanted to immunodeficient mice... - Therapeutic efficacy of human hepatocyte transplantation in a SCID/uPA mouse model with inducible liver diseaseDonna N Douglas
Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
PLoS ONE 5:e9209. 2010..Thus, we reproduced the HSVtk (vTK)/GCV system of hepatic failure in SCID/uPA mice... - Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients databaseChristian Toso
Section of Hepatobiliary, Pancreatic, and Transplant Surgery, University of Alberta, Edmonton, Canada
Hepatology 49:832-8. 2009..A composite patient selection score combining TTV and AFP was the most effective of all tested staging criteria for the prediction of posttransplant patient survival for candidates with HCC... - Anti-HCV therapies in chimeric scid-Alb/uPA mice parallel outcomes in human clinical applicationNorman M Kneteman
Department of Surgery, University of Alberta, Edmonton, Canada
Hepatology 43:1346-53. 2006..In conclusion, this system may help selection of lead compounds for advancement into human trials with an increased likelihood of clinical success while broadening the tools available for study of the biology of HCV infection... - In vivo study of HCV in mice with chimeric human liversNorman M Kneteman
Department of Surgery Faculty of Medicine and Oral Health Sciences, University of Alberta, Edmonton, Canada
Methods Mol Biol 510:383-99. 2009..This chapter reviews development, validation, and early application of a mouse model with a chimeric human liver... - m-TOR inhibitors: what role in liver transplantation?Toshiyasu Kawahara
Division of Transplantation, Department of Surgery, University of Alberta, Canada
J Hepatol 55:1441-51. 2011.... - The estimated number of patients with hepatocellular carcinoma selected for liver transplantation using expanded selection criteriaChristian Toso
Section of Hepatobiliary, Pancreatic and Transplant Surgery, University of Alberta, Edmonton, AB, Canada
Transpl Int 22:869-75. 2009..This data will assist Centers and policy agencies in predicting the need for resources linked to an expansion of criteria... - Five-year follow-up after clinical islet transplantationEdmond A Ryan
Department of Medicine, Clinical Islet Transplant Program, 2000 College Plaza, 8215 112th St, Edmonton, Alberta, Canada T6G 2C8
Diabetes 54:2060-9. 2005..The results, though promising, still point to the need for further progress in the availability of transplantable islets, improving islet engraftment, preserving islet function, and reducing toxic immunosuppression... - Current status of islet cell transplantationJose Oberholzer
Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
Adv Surg 37:253-82. 2003 - TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric miceChunhai Hao
Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada
Cancer Res 64:8502-6. 2004..The results indicate that the recombinant soluble human TRAIL has a profound apoptotic effect on tumor cells but is nontoxic to human hepatocytes in vitro and in vivo... - Liver transplantation in severe hepatic trauma after hepatic artery embolizationIan B Anderson
Department of Surgery and Critical Care, University of Calgary, Alberta, Canada
J Trauma 58:848-51. 2005 - Targeted quantitative mass spectrometric identification of differentially expressed proteins between Bax-expressing and deficient colorectal carcinoma cellsPeng Wang
Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2, Canada
J Proteome Res 8:3403-14. 2009..These results indicate the functional diversity of Bax and provide new research directions to study the biology of Bax-regulated apoptosis... - Characterization of lipid and lipoprotein metabolism in primary human hepatocytesJi Ling
Group on the Molecular and Cell Biology of Lipids and Department of Biochemistry, University of Alberta, Edmonton, Alberta, Canada T6G 2S2
Biochim Biophys Acta 1831:387-97. 2013..Further research needs to be done to maintain liver specific functions of primary human hepatocytes in prolonged cultures for these cells to be a viable model... - Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinomaNorman M Kneteman
Department of Surgery, Section of Hepatobiliary, Pancreatic and Transplantation Surgery, University of Alberta, Edmonton, Alberta T6G 2B7, Canada
Liver Transpl 10:1301-11. 2004..This sirolimus based immunosuppression protocol appears to have beneficial effects on tumor recurrence and survival with an acceptable rate of rejection and toxicity... - Liver trauma: management of devascularization injuriesIan B Anderson
Department of Surgery and Trauma Services, University of Calgary, Calgary, Alberta, Canada
J Trauma 57:1099-104. 2004 - Percutaneous transhepatic pancreatic islet cell transplantation in type 1 diabetes mellitus: radiologic aspectsRichard J T Owen
Departments of Diagnostic Imaging, University of Alberta Hospital, 8440 112th Street, Edmonton, Alberta, Canada T6G 2B7
Radiology 229:165-70. 2003..To report our experience with percutaneous transhepatic pancreatic islet cell transplantation in patients with type 1 diabetes mellitus... - Lipoprotein profiles in SCID/uPA mice transplanted with human hepatocytes become human-like and correlate with HCV infection successRineke H G Steenbergen
Department of Medical Microbiology and Immunology and Li Ka Shing Institute of Virology, Katz Centre for Pharmacy and Health Research, National Canadian Research Training Program in Hepatitis C, Centre de recherche du Centre Hospitalier de l Universite de Montreal, Hopital Saint Luc, Montreal, Quebec, Canada
Am J Physiol Gastrointest Liver Physiol 299:G844-54. 2010..Our data suggest that the weakest link in the HCV infection chain does not appear to be the presence of human hepatocytes per se. We believe that HCV infection also depends on the presence of sufficient levels of human lipoproteins... - Defining optimal immunosuppression for islet transplantation based on reduced diabetogenicity in canine islet autograftsA M James Shapiro
Surgical Medical Research Institute, Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
Transplantation 74:1522-8. 2002..We here explore the effects of clinically relevant doses of cyclosporine or tacrolimus when given alone or in combination with glucocorticoids on long-term canine islet autograft function... - Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cellsPeng Wang
Department of Laboratory Medicine and Pathology and Surgery, University of Alberta, Edmonton, Alberta, Canada
Cell Signal 19:2237-46. 2007..These studies therefore suggest that combination treatment with chemotherapy can overcome TRAIL resistance and enhance TRAIL therapeutic efficacy in treating pancreatic cancers...